186 related articles for article (PubMed ID: 8723457)
21. Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn.
Yang RH; Rong XZ; Hua R; Zhang T
Burns; 2009 Feb; 35(1):75-9. PubMed ID: 18789586
[TBL] [Abstract][Full Text] [Related]
22. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.
Madaras-Kelly KJ; Ostergaard BE; Hovde LB; Rotschafer JC
Antimicrob Agents Chemother; 1996 Mar; 40(3):627-32. PubMed ID: 8851583
[TBL] [Abstract][Full Text] [Related]
23. Ciprofloxacin disposition in elderly patients with LRTI being treated with sequential therapy (200 mg intravenously twice daily followed by 500 mg per os twice daily): comparative pharmacokinetics and the role of therapeutic drug monitoring.
Pea F; Milaneschi R; Baraldo M; Lugatti E; Talmassons G; Furlanut M
Ther Drug Monit; 2000 Aug; 22(4):386-91. PubMed ID: 10942176
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease.
Kontou P; Chatzika K; Pitsiou G; Stanopoulos I; Argyropoulou-Pataka P; Kioumis I
Antimicrob Agents Chemother; 2011 Sep; 55(9):4149-53. PubMed ID: 21670178
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and endometrial tissue concentrations of enrofloxacin and the metabolite ciprofloxacin after i.v. administration of enrofloxacin to mares.
Papich MG; Van Camp SD; Cole JA; Whitacre MD
J Vet Pharmacol Ther; 2002 Oct; 25(5):343-50. PubMed ID: 12423224
[TBL] [Abstract][Full Text] [Related]
26. Relationships between renal function and disposition of oral ciprofloxacin.
Forrest A; Weir M; Plaisance KI; Drusano GL; Leslie J; Standiford HC
Antimicrob Agents Chemother; 1988 Oct; 32(10):1537-40. PubMed ID: 3190182
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of oral ciprofloxacin in continuous cycling peritoneal dialysis.
Yeung SM; Walker SE; Tailor SA; Awdishu L; Tobe S; Yassa T
Perit Dial Int; 2004; 24(5):447-53. PubMed ID: 15490984
[TBL] [Abstract][Full Text] [Related]
28. Aztreonam pharmacokinetics in burn patients.
Friedrich LV; White RL; Kays MB; Brundage DM; Yarbrough D
Antimicrob Agents Chemother; 1991 Jan; 35(1):57-61. PubMed ID: 2014982
[TBL] [Abstract][Full Text] [Related]
29. The ciprofloxacin target AUC : MIC ratio is not reached in hospitalized patients with the recommended dosing regimens.
Haeseker M; Stolk L; Nieman F; Hoebe C; Neef C; Bruggeman C; Verbon A
Br J Clin Pharmacol; 2013 Jan; 75(1):180-5. PubMed ID: 22616681
[TBL] [Abstract][Full Text] [Related]
30. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
Chabot GG; Abigerges D; Catimel G; Culine S; de Forni M; Extra JM; Mahjoubi M; Hérait P; Armand JP; Bugat R
Ann Oncol; 1995 Feb; 6(2):141-51. PubMed ID: 7786822
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group.
Lipman J; Scribante J; Gous AG; Hon H; Tshukutsoane S
Antimicrob Agents Chemother; 1998 Sep; 42(9):2235-9. PubMed ID: 9736541
[TBL] [Abstract][Full Text] [Related]
32. Plasma concentrations of enrofloxacin and its active metabolite ciprofloxacin in dogs following single oral administration of enrofloxacin at 7.5, 10, or 20 mg/kg.
Boothe DM; Boeckh A; Boothe HW; Wilkie S; Jones S
Vet Ther; 2002; 3(4):409-19. PubMed ID: 12584678
[TBL] [Abstract][Full Text] [Related]
33. Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers.
Chukwuani CM; Coker HA; Oduola AM; Sowunmi A; Ifudu ND
Biol Pharm Bull; 2000 Aug; 23(8):968-72. PubMed ID: 10963305
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of gatifloxacin pharmacokinetics and pharmacodynamics in severely ill adults in a medical Intensive Care Unit.
Fish DN
Int J Antimicrob Agents; 2007 Jun; 29(6):715-23. PubMed ID: 17433631
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intramuscular administration of enrofloxacin in goats.
Rao GS; Ramesh S; Ahmad AH; Tripathi HC; Sharma LD; Malik JK
Vet Res Commun; 2001 Apr; 25(3):197-204. PubMed ID: 11334149
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function.
Drusano GL; Weir M; Forrest A; Plaisance K; Emm T; Standiford HC
Antimicrob Agents Chemother; 1987 Jun; 31(6):860-4. PubMed ID: 3619418
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications.
Ding HZ; Yang GX; Huang XH; Chen ZL; Zeng ZL
J Vet Pharmacol Ther; 2008 Jun; 31(3):200-4. PubMed ID: 18471140
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration.
Wallis SC; Mullany DV; Lipman J; Rickard CM; Daley PJ
Intensive Care Med; 2001 Apr; 27(4):665-72. PubMed ID: 11398692
[TBL] [Abstract][Full Text] [Related]
39. Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients.
Abigerges D; Armand JP; Chabot GG; Bruno R; Bissery MC; Bayssas M; Klink-Alakl M; Clavel M; Catimel G
Anticancer Drugs; 1996 Feb; 7(2):166-74. PubMed ID: 8740721
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients.
Mimoz O; Binter V; Jacolot A; Edouard A; Tod M; Petitjean O; Samii K
Intensive Care Med; 1998 Oct; 24(10):1047-51. PubMed ID: 9840238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
